Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Sierra Oncology, Inc. (SRRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/01/2022 8-K Quarterly results
06/29/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
06/22/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/01/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
Docs: "Sierra Oncology Reports First Quarter 2022 Results"
04/13/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, between GlaxoSmithKline plc, Orikum Acquisition Inc., and Sierra Oncology, Inc",
"Form of Support Agreement, by and among GlaxoSmithKline plc, Orikum Acquisition Inc., Sierra Oncology, Inc, and certain securityholders of Sierra Oncology, Inc",
"GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn"
03/10/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
01/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Form of Prefunded Warrant",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation"
01/25/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obl...
Docs: "Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis",
"Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib"
11/05/2021 8-K Quarterly results
Docs: "Letter re: Registration Statement on Form S-3",
"Sierra Oncology Reports Third Quarter 2021 Results – MOMENTUM study on track for topline data read-out by February 2022 – – Global in-licensing deal expands myelofibrosis pipeline and provides options for combination studies in"
09/10/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
12/22/2020 8-K Entry into a Material Definitive Agreement
12/18/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
11/12/2020 8-K Entry into a Material Definitive Agreement
11/05/2020 8-K Quarterly results
Docs: "Sierra Oncology Reports Third Quarter 2020 Results - MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 -"
08/06/2020 8-K Quarterly results
06/11/2020 8-K Submission of Matters to a Vote of Security Holders
06/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/26/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/07/2020 8-K Quarterly results
04/16/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Bylaws",
"Amended and Restated Bylaws"
03/03/2020 8-K Quarterly results
02/06/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Securities Purchase Agreement, by and between the Company and Gilead Sciences, Inc",
"Gilead Warrant"
01/22/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment (Reverse Stock Split) to the Restated Certificate of Incorporation, filed January 22, 2020",
"Sierra Oncology Announces Reverse Stock Split - Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement - VANCOUVER, January 22, 2020 - Sierra Oncology, Inc. , a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40. The reverse stock split will be effective today at 4:30 p.m. Eastern Time. At the market open on January 23, 2020, the Company's common stock will continue..."
01/21/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/26/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy